Source: Pharmaceutics. Unidade: IQSC
Subjects: NEOPLASIAS, QUIMIOTERAPIA
ABNT
MACHADO, Raiane Aparecida dos Santos et al. A new heteroleptic Zn(II) complex with Schiff bases sensitizes triple-negative breast cancer cells to Doxorubicin and Paclitaxel. Pharmaceutics, v. 16, p. 1610, 2024Tradução . . Disponível em: https://doi.org/10.3390/ pharmaceutics16121610. Acesso em: 13 maio 2025.APA
Machado, R. A. dos S., Siqueira, R. P., Silva, F. C. da, Matos, A. C. P. de, Borges, D. S., Rocha, G. G., et al. (2024). A new heteroleptic Zn(II) complex with Schiff bases sensitizes triple-negative breast cancer cells to Doxorubicin and Paclitaxel. Pharmaceutics, 16, 1610. doi:10.3390/ pharmaceutics16121610NLM
Machado RA dos S, Siqueira RP, Silva FC da, Matos ACP de, Borges DS, Rocha GG, Souza TCP de, Souza RAC, Oliveira CR de, Ferreira AG, Maia PI da S, Deflon VM, Oliveira CG, Araújo TG. A new heteroleptic Zn(II) complex with Schiff bases sensitizes triple-negative breast cancer cells to Doxorubicin and Paclitaxel [Internet]. Pharmaceutics. 2024 ;16 1610.[citado 2025 maio 13 ] Available from: https://doi.org/10.3390/ pharmaceutics16121610Vancouver
Machado RA dos S, Siqueira RP, Silva FC da, Matos ACP de, Borges DS, Rocha GG, Souza TCP de, Souza RAC, Oliveira CR de, Ferreira AG, Maia PI da S, Deflon VM, Oliveira CG, Araújo TG. A new heteroleptic Zn(II) complex with Schiff bases sensitizes triple-negative breast cancer cells to Doxorubicin and Paclitaxel [Internet]. Pharmaceutics. 2024 ;16 1610.[citado 2025 maio 13 ] Available from: https://doi.org/10.3390/ pharmaceutics16121610